Journal: Investigative Ophthalmology & Visual Science

Article Title: Integrated Transcriptomics and Experimental Validation Reveal That Ellagic Acid Alleviates Fuchs Endothelial Corneal Dystrophy via PLAU/NF-κB Signaling

doi: 10.1167/iovs.67.1.31

Figure Lengend Snippet: In vitro experiments confirming ellagic acid (EA) target on PLAU to regulate NF-κB signaling pathway in corneal endothelial cells. ( A – C ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in H 2 O 2 -treated B4G12 cells, with or without EA treatment. The relative protein expression levels are shown for B PLAU and C the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( D – F ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in UVA-irradiated B4G12 cells, with or without EA treatment. Relative protein expression levels are shown for E PLAU and F the ratio of phospho-NF-κB p65 to total NF-κB p65 ( n = 3). ( G – I ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 following siPLAU treatment in H 2 O 2 -treated B4G12 cells, with or without EA. Relative protein expression levels are presented for G PLAU and I the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( J ) Schematic diagram illustrating the proposed anti-inflammatory and anti-oxidant mechanisms of EA in FECD, highlighting its role in modulating the NF-κB pathway. All data are presented as mean ± SD. * P < 0.05, ** P < 0.01 by 1-way ANOVA with Tukey’s post hoc test.

Article Snippet: Primary antibodies against PLAU (Proteintech, China; #17968-1-AP), NF-κB p65 (Abcam, UK; #ab32536), phospho-NF-κB p65 (S536; Abcam, UK; #ab76302), GAPDH (ABclonal, China; #AC002), and β-Actin (ABclonal, China; #AC004) were applied overnight at 4°C.

Techniques: In Vitro, Western Blot, Expressing, Irradiation

Journal: Frontiers in Pharmacology

Article Title: Integrated analysis of Dendrobium nobile extract Dendrobin A against pancreatic ductal adenocarcinoma based on network pharmacology, bioinformatics, and validation experiments

doi: 10.3389/fphar.2023.1079539

Figure Lengend Snippet: Expression levels of PLAU protein in PDAC and paraneoplastic tissues. (A) Representative images of PLAU protein in PDAC and control tissues by IHC staining. Bars = 200 μm. (B) Quantitative results of PLAU protein in PDACs and controls, **** p < 0.0001. (C) Correlation between PLAU protein expression in PDAC and tumor differentiation status of patients, ** p < 0.01. (D) Correlation between PLAU protein expression in PDAC and lymph node metastatic status of patients, * p < 0.05.

Article Snippet: Immunohistochemical staining (IHC) was performed using an antibody against PLAU (1:500 dilution, #17968-1-AP, Proteintech, Wuhan, China).

Techniques: Expressing, Control, Immunohistochemistry

Journal: International Journal of Cell Biology

Article Title: Stellettin B Isolated from Stelletta Sp. Reduces Migration and Invasion of Hepatocellular Carcinoma Cells through Reducing Activation of the MAPKs and FAK/PI3K/AKT/mTOR Signaling Pathways

doi: 10.1155/2022/4416611

Figure Lengend Snippet: Stellettin B regulated the expression levels in the PI3K/AKT/mTOR signaling pathway. Western blotting analysis was employed to analyze the expressions levels of p -FAK, p -PI3K, p -AKT, and p -mTOR in HA22T and HepG2 cells treated with Stellettin B. Zero refers to cells treated with DMSO vehicle as a control. β -Actin was used as the internal control.

Article Snippet: Rabbit antibodies against human MMP-2, MMP-9, uPA, PI3K, and p -PI3K were obtained from Cell Signaling Technology Inc. (Danvers, MA, USA).

Techniques: Expressing, Western Blot, Control